---
title: "RVMD.US (RVMD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RVMD.US/news.md"
symbol: "RVMD.US"
name: "RVMD.US"
parent: "https://longbridge.com/en/quote/RVMD.US.md"
datetime: "2026-05-19T22:51:11.552Z"
locales:
  - [en](https://longbridge.com/en/quote/RVMD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RVMD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RVMD.US/news.md)
---

# RVMD.US (RVMD.US) — Related News

### [GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks](https://longbridge.com/en/news/286926662.md)
*2026-05-19T13:50:31.000Z*
> GraniteShares has filed with the SEC to launch three new 2x ETFs focused on high-volatility themes in nuclear energy, AI

### ["Making money" is the secret code to Revolution's hundred billion myth](https://longbridge.com/en/news/286888792.md)
*2026-05-19T09:38:51.000Z*
> Since its IPO, Revolution has raised nearly $7.6 billion, becoming a financing powerhouse in the global biotech sector. 

### [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md)
*2026-05-15T15:47:23.000Z*
> U.S. cancer centers are rapidly enrolling patients in an expanded access program for Revolution Medicines' pancreatic ca

### [NEJM: Has the "nemesis" of pancreatic cancer arrived? This targeted drug makes tumor mutations "nowhere to hide."](https://longbridge.com/en/news/286496724.md)
*2026-05-15T02:25:18.000Z*
> A study published in the New England Journal of Medicine shows that daraxonrasib, as a novel targeted drug, demonstrates

### [US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib](https://longbridge.com/en/news/286405546.md)
*2026-05-14T11:10:39.000Z*
> The FDA has authorized an expanded access program for Revolution Medicines' experimental drug daraxonrasib, aimed at pan

### [$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/285961458.md)
*2026-05-11T14:15:25.000Z*
> Revolution Medicines (NASDAQ:RVMD) has delivered an annualized return of 35.28% over the past 5 years, outperforming the

### [LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)](https://longbridge.com/en/news/285825734.md)
*2026-05-10T01:56:01.000Z*
> LifeSci Capital analyst Charles Zhu has reaffirmed a Buy rating for Revolution Medicines (RVMD), setting a price target